Attention Deficit Hyperactivhity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
NEW YORK, Dec. 14, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0336639/Attention-Deficit-Hyperactivity-Disorder-ADHD-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, "Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global ADHD market. The report identifies the key trends shaping and driving the global ADHD market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ADHD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData estimates that the global Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market was valued at $3855.6m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 8.0% over the next eight years, to reach $7114.5m by 2018. Between 2005 and 2010 three drugs, namely Daytrana (methylphenidate), Vyvanse (lisdexamfetamine) and Intuniv (guanfacine), were approved in the US. Vyvanse has a comparatively lesser potential to cause habituation and drug abuse, this has resulted in high acceptance of Vyvanse in the US despite its high treatment cost in comparison with the existing therapies. In 2009, the authorized generic versions of Adderall XR (mixed amphetamine salt) were launched, which resulted in a decline in the US market, in turn triggering a decline in the global ADHD market in 2009.
Between 2010 and 2018, the global ADHD market is expected to grow at a CAGR of 8%. The growth rate is similar across the US and European countries, but is significantly higher in Japan (18.4%). This disparity across geographical markets exists because of the variation in the approval dates for some of the drugs in the US, Europe and Japan. In the US, therapies such as Vyvanse, Intuniv and Kapvay (clonidine hydrochloride) are already approved, whereas these drugs are not approved in Europe and Japan. The entry of Vyvanse and Intuniv in major European markets is expected in 2012 and 2014 respectively. Vyvanse has a comparatively lesser potential to cause habituation and drug abuse, and its acceptance across Europe is predicted to represent a growth driving factor for the European ADHD market. The other drugs which are expected to enter into the market during the forecast period such as NWP06, CM4612 and RIT124D have a similar mode of action to that of existing drugs, and are therefore unlikely to impact the market significantly.
During this forecast period, patents for various drugs such as Adderall XR, Daytrana, Concerta (methylphenidate), Strattera (atomoxetine) and Kapvay are set to expire. However, the decline in the market valuations due to patent expiries of these drugs is likely to be compensated by the new drugs entering the market such as Vyvanse and Intuniv. Thus, the global ADHD market will register growth through 2010 to 2018.
Scope
The report provides information on the key drivers and challenges of the ADHD market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) ADHD market revenues data from 2005 to 2010, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as norepinephrine-dopamine reuptake inhibitors, selective alpha2A-adrenergic receptor agonists, serotonin-norepinephrine-dopamine reuptake inhibitors, selective serotonin (5-HT1)-dopamine antagonists, serotonin (5-HT1A and 5-HT1B) receptor agonists, highly selective norepinephrine reuptake inhibitors (NRI), antagonist of alcohol-metabolic effects, dopamine partial agonists, alpha 4 beta 2 neuronal nicotinic receptor (NNR) agonists, dopamine antagonists, alpha7 NNR agonists, serotonin and norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors (SSRIs), dopamine (D2) receptors and serotonin type 2 (5-HT2) receptor agonists, alpha 3 beta 2 and alpha 4 beta 2 NNR antagonists, histamine H3 receptor antagonists, selective alpha2A-adrenergic receptor agonists, histamine H3 autoreceptor antagonists, ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor modulators, specific phosphodiesterase 1 (PDE1) inhibitors, dopamine uptake inhibitors and serotonin (5-HT6) receptor antagonists.
- Analysis of the current and future competition in the global ADHD market. Key market players covered are Curemark LLC, Johnson & Johnson, Nextwave Pharmaceuticals, Novartis AG and Shire Plc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the ADHD therapeutics market.
- Analysis of key recent licensing and partnership agreements in ADHD market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global ADHD market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global ADHD market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global ADHD market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Attention Deficit Hyperactivity Disorder (ADHD) - Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 9
2.2.1 Prevalence/Incidence 9
2.2.2 Quality of Life (Qol) 10
2.2.3 Pharmacoeconomic Burden: 11
2.3 Etiology and Pathophysiology 12
2.3.1 Genetic Causes 12
2.3.2 Environmental Causes 12
2.4 Signs and Symptoms 13
2.5 Diagnosis 14
2.5.1 Diagnostic Criteria for ADHD 15
2.5.2 Rating Scales Used for the Diagnosis: 17
2.6 Treatment and Management Options 20
2.6.1 Pharmacologic Treatment: 20
2.6.2 Behavioral therapy 21
2.7 Referral Pathway 21
2.8 GlobalData, Pipeline Report Guidance 23
3 ADHD Therapeutics - Market Characterization 24
3.1 ADHD Therapeutics Market Size (2005–2010) – Global 24
3.2 ADHD Therapeutics Market Forecast (2010–2018) – Global 25
3.3 ADHD Therapeutics Market Size (2005–2010) – The US 26
3.4 ADHD Therapeutics Market Forecast (2010–2018) – The US 27
3.5 ADHD Therapeutics Market Size (2005–2010) – France 28
3.6 ADHD Therapeutics Market Forecast (2010–2018) – France 29
3.7 ADHD Therapeutics Market Size (2005–2010) – Germany 30
3.8 ADHD Therapeutics Market Forecast (2010–2018) – Germany 31
3.9 ADHD Therapeutics Market Size (2005–2010) – Italy 32
3.10 ADHD Therapeutics Market Forecast (2010–2018) – Italy 33
3.11 ADHD Therapeutics Market Size (2005–2010) – Spain 34
3.12 ADHD Therapeutics Market Forecast (2010–2018) – Spain 35
3.13 ADHD Therapeutics Market Size (2005–2010) – The UK 36
3.14 ADHD Therapeutics Market Forecast (2010–2018) – The UK 37
3.15 ADHD Therapeutics Market Size (2005–2010) – Japan 38
3.16 ADHD Therapeutics Market Forecast (2010–2018) – Japan 39
3.17 Drivers and Barriers for the ADHD Therapeutics Market 40
3.17.1 Drivers for the ADHD Therapeutics Market 40
3.17.2 Barriers for the ADHD Therapeutics Market 40
3.18 Opportunity and Unmet Need Analysis 42
3.19 Key Takeaway 43
4 ADHD Therapeutics - Competitive Assessment 44
4.1 Overview 44
4.2 Strategic Competitor Assessment 44
4.3 Product Profiles for the Major Marketed Products in the ADHD Therapeutics Market 45
4.3.1 Ritalin LA (methylphenidate hydrochloride long acting capsules) 45
4.3.2 Adderall XR (Mixed amphetamine salt) 46
4.3.3 Daytrana (methylphenidate transdermal system) 48
4.3.4 Vyvanse (lisdexamfetamine dimesylate) 51
4.3.5 Concerta (methylphenidate hydrochloride) 54
4.3.6 Strattera (atomoxetine hydrochloride) 57
4.3.7 Intuniv (guanfacine) 59
4.3.8 Kapvay (clonidine hydrochloride) 60
4.4 Key Takeaway 62
5 ADHD Therapeutics - Pipeline Assessment 63
5.1 Overview 63
5.2 Strategic Pipeline Assessment 63
5.3 ADHD Therapeutics Pipeline – Pipeline by Phases of Development 64
5.3.1 ADHD Therapeutics – Filed Pipeline 64
5.3.2 ADHD Therapeutics – Phase III Pipeline 65
5.3.3 ADHD Therapeutics – Phase II/III Pipeline 65
5.3.4 ADHD Therapeutics – Phase II Pipeline 66
5.3.5 ADHD Therapeutics – Phase I Pipeline 67
5.3.6 ADHD Therapeutics – Pre-Clinical Pipeline 67
5.3.7 Technology Trends Analytic Framework 68
5.4 ADHD Therapeutics Market –Clinical Pipeline by Mechanism of Action 70
5.5 ADHD Therapeutics – Promising Drugs under Clinical Development 70
5.6 Molecule Profile for Promising Drug Under Clinical Development 71
5.6.1 NWP06 71
5.6.2 CM-4612 71
5.6.3 RIT124D 71
5.6.4 JNS001 71
5.7 Key Takeaway 71
6 ADHD Therapeutics - Clinical Trials Mapping 72
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 72
6.2 Clinical Trials by Phase 73
6.3 Clinical Trials by Trial Status 74
6.4 Prominent Sponsors 75
6.5 Top Companies Participating in ADHD Therapeutics Clinical Trials 77
7 Strategic Assessment 78
7.1 Key Events Impacting the Future Market 78
7.2 ADHD Therapeutics: Implications for Future Market Competition 79
8 ADHD Therapeutics - Future Players 80
8.1 Introduction 80
8.2 Company Profiles 80
8.2.1 Curemark, LLC. 80
8.2.2 Johnson & Johnson 81
8.2.3 NextWave Pharmaceuticals 83
8.2.4 Novartis AG 84
8.2.5 Shire Plc. 86
8.2.6 Other Companies in the ADHD Therapeutics Market 88
9 ADHD Therapeutics - Licensing and Partnership Deals 91
10 ADHD Therapeutics - Appendix 95
10.1 Market Definitions 95
10.2 Abbreviations 95
10.3 Methodology 96
10.3.1 Coverage 96
10.3.2 Secondary Research 97
10.3.3 Forecasting 97
10.3.4 Primary Research 99
10.3.5 Expert Panel Validation 100
10.4 Contact Us 100
10.5 Disclaimer 100
10.6 Bibliography 100
List of Tables
Table 1: ADHD Therapeutics- Comorbidities 8
Table 2: Prevalence of subtypes of ADHD as per KiGGS 10
Table 3: Common Assessment Scales used to aid the diagnosis of ADHD 17
Table 4: Rating Scales used for the diagnosis of childhood, adolescent and adult ADHD 18
Table 5: Drugs commonly prescribed for ADHD 20
Table 6: ADHD Therapeutics Market, Global, Revenue ($m), 2005–2010 24
Table 7: ADHD Therapeutics Market, Global, Forecasts ($m), 2010–2018 25
Table 8: ADHD Therapeutics Market, The US, Revenue ($m), 2005–2010 26
Table 9: ADHD Therapeutics Market, The US, Forecasts ($m), 2010–2018 27
Table 10: ADHD Therapeutics Market, France, Revenue ($m), 2005–2010 28
Table 11: ADHD Therapeutics Market, France, Forecasts ($m), 2010–2018 29
Table 12: ADHD Therapeutics Market, Germany, Revenue ($m), 2005–2010 30
Table 13: ADHD Therapeutics Market, Germany, Forecasts ($m), 2010–2018 31
Table 14: ADHD Therapeutics Market, Italy, Revenue ($m), 2005–2010 32
Table 15: ADHD Therapeutics Market, Italy, Forecasts ($m), 2010–2018 33
Table 16: ADHD Therapeutics Market, Spain, Revenue ($m), 2005–2010 34
Table 17: ADHD Therapeutics Market, Spain, Forecasts ($m), 2010–2018 35
Table 18: ADHD Therapeutics Market, Spain, Revenue ($m), 2005–2010 36
Table 19: ADHD Therapeutics Market, The UK, Forecasts ($m), 2010–2018 37
Table 20: ADHD Therapeutics Market, Japan, Revenue ($m), 2005–2010 38
Table 21: ADHD Therapeutics Market, Japan, Forecasts ($m), 2010–2018 39
Table 22: Adverse Events Associated with Adderall XR 47
Table 23: Clinical Studies for Adderall XR 47
Table 24: Adverse Events Associate with Daytrana 49
Table 25: Clinical Studies for Daytrana 50
Table 26: ADHD Therapeutics- Adverse Events Associated with Vyvanse 52
Table 27: Clinical Studies for Vyvanse 53
Table 28: Common Treatment Emergent Adverse Events Associated with Concerta 55
Table 29: Clinical Studies for Concerta 56
Table 30: Common Treatment Emergent Adverse Events Associated with Strattera 58
Table 31: Clinical Studies for Strattera 58
Table 32: Common treatment Emergent Adverse Events Associated with Intuniv 59
Table 33: Clinical Studies for Intuniv 60
Table 34: Common Adverse Events Associated with Kapvay in Children and Adolescents 61
Table 35: Clinical Studies for Kapvay 61
Table 36: ADHD Therapeutics, Filed Pipeline, 2011 64
Table 37: ADHD Therapeutics, Phase III Pipeline, 2011 65
Table 38: ADHD Therapeutics, Phase II/III Pipeline, 2011 65
Table 39: ADHD Therapeutics, Phase II Pipeline, 2011 66
Table 40: ADHD Therapeutics, Phase I Pipeline, 2011 67
Table 41: ADHD Therapeutics, Pre-Clinical Pipeline, 2011 67
Table 42: ADHD Therapeutics, Most Promising Drugs Under Clinical Development, 2011 70
Table 43: ADHD Therapeutics, Clinical Trials by Country, 2011 72
Table 44: ADHD Therapeutics - Clinical Trials by Phase, 2011 73
Table 45: ADHD Therapeutics, Clinical Trials by Status (%), 2011 74
Table 46: ADHD Therapeutics, Prominent Sponsors, 2011 76
Table 47: ADHD Therapeutics, Top Companies Participating in Clinical Trials, 2011 77
Table 48: Curemark LLC., ADHD Pipeline, 2011 81
Table 49: Curemark LLC., CNS Pipeline, 2011 81
Table 50: Johnson & Johnson, ADHD Pipeline, 2011 83
Table 51: Johnson & Johnson, CNS Pipeline, 2011 83
Table 52: NextWave Pharmaceuticals, ADHD Pipeline, 2011 83
Table 53: NextWave Pharmaceuticals, CNS Pipeline, 2011 83
Table 54: Novartis ADHD Pipeline, 2011 85
Table 55: Novartis, CNS Pipeline, 2011 85
Table 56: Shire Plc., ADHD Pipeline, 2011 87
Table 57: Shire Plc., CNS Pipeline, 2011 87
Table 58: ADHD Therapeutics Market, Future Players 88
Table 59: ADHD Therapeutics, Global, Deals, 2009-2011 91
1.2 List of Figures
Figure 1: Co-existing Conditions in ADHD 8
Figure 2: A Three-Dimensional, High-Resolution MRI Image of the Brain of A Patient with ADHD 12
Figure 3: ADHD Therapeutics- Symptoms 13
Figure 4: ADHD Therapeutics – Diagnosis Of ADHD 14
Figure 5: ADHD Therapeutics – Barkley Home Situations Questionnaire (HSQ) 18
Figure 6: ADHD Therapeutics - Adult Self Report Scale VI.I (ASRS-VI.I) Screener 19
Figure 7: ADHD Therapeutics - Referral Pathway 22
Figure 8: ADHD Therapeutics Market, Global, Revenue ($m), 2005–2010 24
Figure 9: ADHD Therapeutics Market, Global, Forecast ($m), 2010–2018 25
Figure 10: ADHD Therapeutics Market, The US, Revenue ($m), 2005–2010 26
Figure 11: ADHD Therapeutics Market, The US, Forecast ($m), 2010–2018 27
Figure 12: ADHD Therapeutics Market, France, Revenue ($m), 2005–2010 28
Figure 13: ADHD Therapeutics Market, France, Forecast ($m), 2010–2018 29
Figure 14: ADHD Therapeutics Market, Germany, Revenue ($m), 2005–2010 30
Figure 15: ADHD Therapeutics Market, Germany, Forecast ($m), 2010–2018 31
Figure 16: ADHD Therapeutics Market, Italy, Revenue ($m), 2005–2010 32
Figure 17: ADHD Therapeutics Market, Italy, Forecast ($m), 2010–2018 33
Figure 18: ADHD Therapeutics Market, Spain, Revenue ($m), 2005–2010 34
Figure 19: ADHD Therapeutics Market, Spain, Forecast ($m), 2010–2018 35
Figure 20: ADHD Therapeutics Market, The UK, Revenue ($m), 2005–2010 36
Figure 21: ADHD Therapeutics Market, The UK, Forecast ($m), 2010–2018 37
Figure 22: ADHD Therapeutics Market, Japan, Revenue ($m), 2005–2010 38
Figure 23: ADHD Therapeutics Market, Japan, Forecast ($m), 2010–2018 39
Figure 24: Opportunity and Unmet Need in the ADHD Therapeutics Market, 2010 42
Figure 25: ADHD Therapeutics, Strategic Competitor Assessment, 2010 45
Figure 26: ADHD Therapeutics – Pipeline by Phase of Development, 2011 64
Figure 27: ADHD Therapeutics, Technology Trends Analytics Framework, 2011 68
Figure 28: ADHD Therapeutics, Technology Trends Analytics Framework, Description, 2011 69
Figure 29: ADHD Therapeutics, Pipeline by Mechanism of Action (%), 2011 70
Figure 30: ADHD Therapeutics - Clinical Trials by Country, 2011 72
Figure 31: ADHD Therapeutics, Clinical Trials by Phase (%), 2011 73
Figure 32: ADHD Therapeutics, Clinical Trials by Status (%), 2011 74
Figure 33: ADHD Therapeutics, Overall sponsors (%), 2011 75
Figure 34: ADHD Therapeutics, Prominent Sponsors (%), 2011 76
Figure 35: ADHD Therapeutics, Top Companies Participating in Clinical Trials, 2011 77
Figure 36: ADHD Therapeutics Market, Drivers and Restraints, 2011 78
Figure 37: Implications for Future Market Competition in the ADHD Market, 2011 79
Figure 38: ADHD Therapeutics Market, Pipeline by Company, 2011 80
Figure 39: GlobalData, Market Forecasting Model 99
Companies mentioned
Curemark, LLC.
Johnson & Johnson
NextWave Pharmaceuticals
Novartis AG
Shire Plc.
To order this report:
Pathology Industry: Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article